Fmoc-L-Chg(3-Me)-OH

Nombre químico: N-alpha-(9-Fluorenylmethyloxycarbonyl)-L-methyl-cyclohexylglycine // Sinónimos: (S)-2-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-2-(1-methylcyclohexyl)acetic acid, (2S)-2-(Fmoc-amino)-2-(1-methylcyclohexyl)acetic acid, N-Fmoc-b-methyl cyclohexyl glycine,N-alpha-(9-Fluorenylmet hyloxycarbonyl)-2-(1-methylcyclohexyl)acetic acid,

  • Nº Artículo:FAA8510
  • Nº CAS:2350460-04-5
  • Fórmula:C24H27NO4
  • Storage temperature:2-8°C
  • Masa molecular:393,48 g/mol

from 900,00 €

Grouped product items
Cantidad Unidad de venta Precio Unidad de almacenamiento de stock (SKU) Disponibilidad
1 g
900,00 €
FAA8510.0001
peticón
description

This Fmoc-protected-b-methyl cyclohexyl glycine derivative can be used for structure-activity-relationship studies to optimize potency and the pharmacokinetic profile of drug candidates. Sidechain-derivatized amino acids have shown great potential in enhancing select properties of lead compounds. Besides the phenyl and bicyclo[1.1.1]pentane motif, cyclohexyl moieties may be employed to optimize binding of promising lead structures.


references

Scaleable catalytic asymmetric Strecker syntheses of unnatural alpha-amino acid; S. J. Zuend, M. P. Coughlin, M. P. Lalonde, E. N. Jacobsen; Nature 2009: 461(7266): 968-70. https://doi.org/10.1038/nature08484


Novel potent inhibitors of hepatitis C virus (HCV) NS3 protease with cyclic sulfonyl P3 cappings; K. X. Chen, B. Vibulbhan, W. Yang, L. G. Nair, X. Tong, K.-C. Cheng, F. G. Njoroge; Bioorg. Med. Chem. Lett. 2009; 19(4): 1105-1109. https://doi.org/10.1016/j.bmcl.2008.12.111


Second-Generation Highly Potent and Selective Inhibitors of the Hepatitis C Virus NS3 Serine Protease; K. X. Chen, L. Nair, B. Vibulbhan, W. Yang, A. Arasappan, S. L. Bogen, S. Venkatraman, F. Bennett, W. Pan, M. L. Blackman, A. I. Padilla, A. Prongay, K.-C. Cheng, X. Tong, N.-Y. Shih, F. G. Njoroge; J. Med. Chem. 2009; 52(5): 1370-1379. https://doi.org/10.1021/jm801238q


Azepanone-based inhibitors of human cathepsin S: Optimization of selectivity via the P2 substituent; J. K. Kerns, H. Nie, W. Bondinell, K. L. Widdowson, D. S. Yamashita, A. Rahman, P. L. Podolin, D. C. Carpenter, Q. Jin, B. Riflade, X. Dong, N. Nevins, P. M. Keller, L. Mitchell. T. Tomaszek; Bioorg. Med. Chem. Lett. 2011; 21(15): 4409-4415. https://doi.org/10.1016/j.bmcl.2011.06.045


* Disclaimer
We refer to our general terms and conditions.
All information contained in our webshop is compiled to the best of our knowledge.
Prices and product availability are subject to change and require reconfirmation. Please contact us for further information.

¿Necesita más información sobre este producto?

ponerse en contacto

Contacto rápido

Por favor envíeme más información sobre

¡Otros productos que también podrían interesarle!